Management of Severe Hypertension, Hypertension in Special Condition
Evaluation and management of hypertension
-
Upload
nagesh-waghmare -
Category
Health & Medicine
-
view
692 -
download
0
Transcript of Evaluation and management of hypertension
![Page 1: Evaluation and management of hypertension](https://reader033.fdocuments.us/reader033/viewer/2022051314/559714331a28ab47108b47cb/html5/thumbnails/1.jpg)
Evaluation and Management of
Hypertension
Prof. Dr. S.C. Mandal
Dr. Nagesh Waghmare (DM student)
Cardiology, ICVS
IPGME&R, Kolkata
![Page 2: Evaluation and management of hypertension](https://reader033.fdocuments.us/reader033/viewer/2022051314/559714331a28ab47108b47cb/html5/thumbnails/2.jpg)
1. What is hypertension ?
2. Why should we treat it ?
3. Causes and mechanisms
4. Diagnosis and Initial evaluation
5. Treatment
6. Recent advances
![Page 3: Evaluation and management of hypertension](https://reader033.fdocuments.us/reader033/viewer/2022051314/559714331a28ab47108b47cb/html5/thumbnails/3.jpg)
What is hypertension ?
![Page 4: Evaluation and management of hypertension](https://reader033.fdocuments.us/reader033/viewer/2022051314/559714331a28ab47108b47cb/html5/thumbnails/4.jpg)
Hypertension paradox
• Can be easily diagnosed, but…
• Asymptomatic nature, delays diagnosis
• Advanced therapy available, but…
• Controlled in less than 1/3 rd of patients
Silent Killer
![Page 5: Evaluation and management of hypertension](https://reader033.fdocuments.us/reader033/viewer/2022051314/559714331a28ab47108b47cb/html5/thumbnails/5.jpg)
JNC 7 staging
![Page 6: Evaluation and management of hypertension](https://reader033.fdocuments.us/reader033/viewer/2022051314/559714331a28ab47108b47cb/html5/thumbnails/6.jpg)
Determinants
• Behavioral
– Nicotine
– Heavy drinkers
– Physical inactivity
– Diet low in fresh fruits and high in calories /
sodium.
• Genetic
![Page 7: Evaluation and management of hypertension](https://reader033.fdocuments.us/reader033/viewer/2022051314/559714331a28ab47108b47cb/html5/thumbnails/7.jpg)
Why should we treat it ?
• It affects 1 billion people worldwide
• India has become ―Capital of hypertension‖
• Burden is further rising
![Page 8: Evaluation and management of hypertension](https://reader033.fdocuments.us/reader033/viewer/2022051314/559714331a28ab47108b47cb/html5/thumbnails/8.jpg)
• In the ICMR study in 1994 demonstrated
25% and 29% prevalence of hypertension
among males and females respectively in urban
Delhi and 13% and 10% in rural Haryana.
![Page 9: Evaluation and management of hypertension](https://reader033.fdocuments.us/reader033/viewer/2022051314/559714331a28ab47108b47cb/html5/thumbnails/9.jpg)
• High BP causes
~ 54% of stroke
~ 47% of ischemic heart disease
• It also leads to
– Heart failure
– Peripheral vascular disease
– Renal failure
– Blindness due retinopathy, haemorrhages
![Page 10: Evaluation and management of hypertension](https://reader033.fdocuments.us/reader033/viewer/2022051314/559714331a28ab47108b47cb/html5/thumbnails/10.jpg)
![Page 11: Evaluation and management of hypertension](https://reader033.fdocuments.us/reader033/viewer/2022051314/559714331a28ab47108b47cb/html5/thumbnails/11.jpg)
Absolute benefits of treating hypertension
![Page 12: Evaluation and management of hypertension](https://reader033.fdocuments.us/reader033/viewer/2022051314/559714331a28ab47108b47cb/html5/thumbnails/12.jpg)
Impact of a 5 mmHg Reduction
Overall Reduction
Stroke 14%
Coronary Heart Disease 9%
All Cause Mortality 7%
Hypertension 2003;289:2560-2572.
![Page 13: Evaluation and management of hypertension](https://reader033.fdocuments.us/reader033/viewer/2022051314/559714331a28ab47108b47cb/html5/thumbnails/13.jpg)
So by controlling BP, we can
reduce deaths especially due to stroke
and MI.
![Page 14: Evaluation and management of hypertension](https://reader033.fdocuments.us/reader033/viewer/2022051314/559714331a28ab47108b47cb/html5/thumbnails/14.jpg)
Causes and mechanisms
![Page 15: Evaluation and management of hypertension](https://reader033.fdocuments.us/reader033/viewer/2022051314/559714331a28ab47108b47cb/html5/thumbnails/15.jpg)
• Primary hypertension
– In 90 – 95% of patients, a single reversible
cause cannot be identified
– Also called as Essential hypertension
• Secondary hypertension
– In 5 -10 % of patients
– May be curable
![Page 16: Evaluation and management of hypertension](https://reader033.fdocuments.us/reader033/viewer/2022051314/559714331a28ab47108b47cb/html5/thumbnails/16.jpg)
Primary hypertension
• It is divided in to 3 subtypes –
1. Systolic hypertension of young
• Between 17 -25 years of age
• Probably due to overactive sympathetic nervous
system
![Page 17: Evaluation and management of hypertension](https://reader033.fdocuments.us/reader033/viewer/2022051314/559714331a28ab47108b47cb/html5/thumbnails/17.jpg)
2. Diastolic hypertension in middle age
• Typically 30-50 years of age
• Elevated systemic vascular resistance
• Reduced ability to excrete sodium by kidney
![Page 18: Evaluation and management of hypertension](https://reader033.fdocuments.us/reader033/viewer/2022051314/559714331a28ab47108b47cb/html5/thumbnails/18.jpg)
3. Isolated systolic hypertension in older
adults
• After the age 55 years
• Most common form
• Due to age dependent stiffening of vessels
![Page 19: Evaluation and management of hypertension](https://reader033.fdocuments.us/reader033/viewer/2022051314/559714331a28ab47108b47cb/html5/thumbnails/19.jpg)
![Page 20: Evaluation and management of hypertension](https://reader033.fdocuments.us/reader033/viewer/2022051314/559714331a28ab47108b47cb/html5/thumbnails/20.jpg)
Mechanisms
• Neural
Sympathetic overactivity –
Deactivation of inhibitory neural inputs (e.g.
baroreceptors)
Activation of excitatory inputs (carotid body, renal
afferents)
• Vascular - endothelial cell dysfunction
• Hormonal - Renin- Angiotensin-
Aldosterone system
![Page 21: Evaluation and management of hypertension](https://reader033.fdocuments.us/reader033/viewer/2022051314/559714331a28ab47108b47cb/html5/thumbnails/21.jpg)
![Page 22: Evaluation and management of hypertension](https://reader033.fdocuments.us/reader033/viewer/2022051314/559714331a28ab47108b47cb/html5/thumbnails/22.jpg)
![Page 23: Evaluation and management of hypertension](https://reader033.fdocuments.us/reader033/viewer/2022051314/559714331a28ab47108b47cb/html5/thumbnails/23.jpg)
![Page 24: Evaluation and management of hypertension](https://reader033.fdocuments.us/reader033/viewer/2022051314/559714331a28ab47108b47cb/html5/thumbnails/24.jpg)
Diagnosis and Initial evaluation
![Page 25: Evaluation and management of hypertension](https://reader033.fdocuments.us/reader033/viewer/2022051314/559714331a28ab47108b47cb/html5/thumbnails/25.jpg)
Minimal laboratory testing required for the initial evaluation
• Blood electrolyte values,
• Fasting glucose concentration, and
• Serum creatinine level with calculated
glomerular filtration rate (GFR)
• Serum uric acid
![Page 26: Evaluation and management of hypertension](https://reader033.fdocuments.us/reader033/viewer/2022051314/559714331a28ab47108b47cb/html5/thumbnails/26.jpg)
• Fasting lipid panel
• Hematocrit
• Spot urinalysis, including urine albumin-to-
creatinine ratio
• Resting 12-lead electrocardiogram.
![Page 27: Evaluation and management of hypertension](https://reader033.fdocuments.us/reader033/viewer/2022051314/559714331a28ab47108b47cb/html5/thumbnails/27.jpg)
3 goals
• Initial evaluation should accomplish –
1. Accurate measurement of BP
2. Assessment of patients cardiovascular risk
3. Detection of secondary forms
![Page 28: Evaluation and management of hypertension](https://reader033.fdocuments.us/reader033/viewer/2022051314/559714331a28ab47108b47cb/html5/thumbnails/28.jpg)
Measurement of BP
• Office BP measurement
• Self monitoring at home
• Ambulatory monitoring
![Page 29: Evaluation and management of hypertension](https://reader033.fdocuments.us/reader033/viewer/2022051314/559714331a28ab47108b47cb/html5/thumbnails/29.jpg)
BP Measurement Techniques
Method Brief Description
In-office
• Two readings, 5 minutes apart
• Sitting in chair, not on exam table
• Confirm elevated reading in
contralateral arm
Self-
measuremen
t
• Provides information on response to
therapy
• May help improve adherence to therapy
• Evaluate ―white-coat‖ HTN
![Page 30: Evaluation and management of hypertension](https://reader033.fdocuments.us/reader033/viewer/2022051314/559714331a28ab47108b47cb/html5/thumbnails/30.jpg)
BP Measurement Techniques
Method Brief Description
In-office
Two readings, 5 minutes apart. Sitting in chair, not on
exam table. Confirm elevated reading in contralateral
arm.
Self-measurement
Provides information on response to therapy. May help
improve adherence to therapy and evaluate ―white-coat‖
HTN.
Ambulatory BP
monitoring
Indicated for evaluation of ―white-coat‖
HTN.
Can be used to confirm self-
measurement when inconsistent with in-
office measurement.
![Page 31: Evaluation and management of hypertension](https://reader033.fdocuments.us/reader033/viewer/2022051314/559714331a28ab47108b47cb/html5/thumbnails/31.jpg)
Self-Measurement of BP
Improves awareness and adherence
Instruction on proper use and technique should be
provided
Home measurement devices should:
• Have an arm cuff
• Be checked in office regularly
Validated meters:
BMJ 2001;322:531-536.
omronhealthcare.com
Dableducational.com
Daily Logs
![Page 32: Evaluation and management of hypertension](https://reader033.fdocuments.us/reader033/viewer/2022051314/559714331a28ab47108b47cb/html5/thumbnails/32.jpg)
Self-Measurement of BP
Home measurements of >135/85 mmHg
(or 125/75 in diabetes or renal disease)
are considered hypertensive
At least 50% of measurements should
be at or below goal
![Page 33: Evaluation and management of hypertension](https://reader033.fdocuments.us/reader033/viewer/2022051314/559714331a28ab47108b47cb/html5/thumbnails/33.jpg)
• Ambulatory monitoring also useful for
diagnosis of
– Nocturnal hypertension
– Baro-reflex impairment
• Wrist monitors are inaccurate and thus not
recommended
![Page 34: Evaluation and management of hypertension](https://reader033.fdocuments.us/reader033/viewer/2022051314/559714331a28ab47108b47cb/html5/thumbnails/34.jpg)
Recommended normal values
Average daytime BP < 135 / 85 mm Hg
Night time BP <120 / 70
24-hour BP < 130 / 80
![Page 35: Evaluation and management of hypertension](https://reader033.fdocuments.us/reader033/viewer/2022051314/559714331a28ab47108b47cb/html5/thumbnails/35.jpg)
![Page 36: Evaluation and management of hypertension](https://reader033.fdocuments.us/reader033/viewer/2022051314/559714331a28ab47108b47cb/html5/thumbnails/36.jpg)
Assessment of patients cardiovascular risk
• High-risk patients now includes most
cardiology patients—
1. Established CAD, CAD risk equivalents,
2. Carotid artery disease,
3. Peripheral artery disease,
4. Abdominal aortic aneurysm,
5. Heart failure, or
6. High risk for CAD (10-year framingham risk
score of >10%
![Page 37: Evaluation and management of hypertension](https://reader033.fdocuments.us/reader033/viewer/2022051314/559714331a28ab47108b47cb/html5/thumbnails/37.jpg)
Subclinical Target Organ Damage
• Left ventricular hypertrophy
• Carotid wall thickening or plaque
• Low estimated glomerular filtration rate
=60 mL/min/1.73 m
• Microalbuminuria
• Ankle-brachial BP index <0.9
![Page 38: Evaluation and management of hypertension](https://reader033.fdocuments.us/reader033/viewer/2022051314/559714331a28ab47108b47cb/html5/thumbnails/38.jpg)
This left ventricle is very thickened (slightly over 2 cm in
thickness), but the rest of the heart is not greatly enlarged.
This is typical for hypertensive heart disease. The
hypertension creates a greater pressure load on the heart to
induce the hypertrophy.
![Page 39: Evaluation and management of hypertension](https://reader033.fdocuments.us/reader033/viewer/2022051314/559714331a28ab47108b47cb/html5/thumbnails/39.jpg)
Established Target Organ Damage
• CNS: ischemic stroke, cerebral hemorrhage, transient
ischemic attack
• Heart disease: MI, angina, coronary
revascularization, heart failure
• Renal disease: diabetic nephropathy, renal impairment
• Peripheral arterial disease
• Advanced retinopathy: hemorrhages or
exudates, papilledema
![Page 40: Evaluation and management of hypertension](https://reader033.fdocuments.us/reader033/viewer/2022051314/559714331a28ab47108b47cb/html5/thumbnails/40.jpg)
Identifiable (secondary) forms of hypertension
• Renal disease is the most common cause (2-5%)
• Endocrine diseases
– Phaeochomocytoma
– Cusings syndrome
– Conn’s syndrome
– Acromegaly and hypothyroidism
• Coarctation of the aorta
• Iatrogenic
– Hormonal / oral contraceptive
– NSAIDs
![Page 41: Evaluation and management of hypertension](https://reader033.fdocuments.us/reader033/viewer/2022051314/559714331a28ab47108b47cb/html5/thumbnails/41.jpg)
Clinical clues for Renovascular HT
• Onset before 30 years or after 50 years
• Abrupt onset
• Severe or resistant hypertension
• Symptoms of atherosclerotic disease
elsewhere
![Page 42: Evaluation and management of hypertension](https://reader033.fdocuments.us/reader033/viewer/2022051314/559714331a28ab47108b47cb/html5/thumbnails/42.jpg)
• Negative family history of hypertension
• Smoker
• Worsening renal function after renin-
angiotensin inhibition
• Recurrent ―flash‖ pulmonary edema
![Page 43: Evaluation and management of hypertension](https://reader033.fdocuments.us/reader033/viewer/2022051314/559714331a28ab47108b47cb/html5/thumbnails/43.jpg)
• Examination shows -
Abdominal bruits
Other bruits
Advanced fundal changes
![Page 44: Evaluation and management of hypertension](https://reader033.fdocuments.us/reader033/viewer/2022051314/559714331a28ab47108b47cb/html5/thumbnails/44.jpg)
Hypertensive crisis
• Hypertensive emergencies –
– Malignant hypertension
– Accelerated hypertension
• Hypertensive urgencies
![Page 45: Evaluation and management of hypertension](https://reader033.fdocuments.us/reader033/viewer/2022051314/559714331a28ab47108b47cb/html5/thumbnails/45.jpg)
Treatment
![Page 46: Evaluation and management of hypertension](https://reader033.fdocuments.us/reader033/viewer/2022051314/559714331a28ab47108b47cb/html5/thumbnails/46.jpg)
"The Goal is to Get to Goal!”
Hypertension-PLUS-
Diabetes or Renal Disease
< 140/90 mmHg < 130/80 mmHg
Measurements and goals
should be provided to the
patient verbally and in writing
at each office visit
![Page 47: Evaluation and management of hypertension](https://reader033.fdocuments.us/reader033/viewer/2022051314/559714331a28ab47108b47cb/html5/thumbnails/47.jpg)
Treatment Overview
• Lifestyle modification
Same as for prevention
• Pharmacologic treatment
Initial therapy
Combination therapy
• What to do when a patient is still not at goal?
• Follow-up and monitoring
![Page 48: Evaluation and management of hypertension](https://reader033.fdocuments.us/reader033/viewer/2022051314/559714331a28ab47108b47cb/html5/thumbnails/48.jpg)
Lifestyle Modification
ModificationApproximate SBP
Reduction (range)
Weight reduction 5-20 mmHg/ 10 kg weight loss
Adopt DASH eating
plan8-14 mmHg
Dietary sodium
reduction2-8 mmHg
Physical activity 4-9 mmHg
Moderation of alcohol
consumption2-4 mmHg
JNC 7 Express. JAMA. 2003 Sep 10; 290(10):1314
![Page 49: Evaluation and management of hypertension](https://reader033.fdocuments.us/reader033/viewer/2022051314/559714331a28ab47108b47cb/html5/thumbnails/49.jpg)
DASH Eating Plan
• Low in saturated fat, cholesterol, and total fat
• Emphasizes fruits, vegetables, and low fat diary
products
• Reduced red meat, sweets, and sugar containing
beverages
• Rich in
magnesium, potassium, calcium, protein, and fiber
• 3 -1.5 g sodium per day
• Can reduce BP in 2 weeks
Sacks FM. NEJM. 2001; 344:3-10.
![Page 50: Evaluation and management of hypertension](https://reader033.fdocuments.us/reader033/viewer/2022051314/559714331a28ab47108b47cb/html5/thumbnails/50.jpg)
Pharmacological treatment
![Page 51: Evaluation and management of hypertension](https://reader033.fdocuments.us/reader033/viewer/2022051314/559714331a28ab47108b47cb/html5/thumbnails/51.jpg)
Algorithm for decision
![Page 52: Evaluation and management of hypertension](https://reader033.fdocuments.us/reader033/viewer/2022051314/559714331a28ab47108b47cb/html5/thumbnails/52.jpg)
Compelling indications
These are the associated comorbid
conditions, in which a particular
antihypertensive drug causes major
improvement outcome independent of BP
reduction
![Page 53: Evaluation and management of hypertension](https://reader033.fdocuments.us/reader033/viewer/2022051314/559714331a28ab47108b47cb/html5/thumbnails/53.jpg)
Condition Drug
![Page 54: Evaluation and management of hypertension](https://reader033.fdocuments.us/reader033/viewer/2022051314/559714331a28ab47108b47cb/html5/thumbnails/54.jpg)
![Page 55: Evaluation and management of hypertension](https://reader033.fdocuments.us/reader033/viewer/2022051314/559714331a28ab47108b47cb/html5/thumbnails/55.jpg)
Algorithm of therapy
![Page 56: Evaluation and management of hypertension](https://reader033.fdocuments.us/reader033/viewer/2022051314/559714331a28ab47108b47cb/html5/thumbnails/56.jpg)
When a Patient is Still Not at Goal?
• Optimize dosages or add additional drugs until
goal blood pressure is achieved
• What do you do when you are using several
effective medications?
– Consider causes of resistant hypertension
– Assure drug therapy is rational
– ―Tricks of the trade‖
![Page 57: Evaluation and management of hypertension](https://reader033.fdocuments.us/reader033/viewer/2022051314/559714331a28ab47108b47cb/html5/thumbnails/57.jpg)
Causes of inadequate response to therapy
• Pseudo-resistance
• Non-adherence to therapy
• Drug related causes
• Associated condotions
• Secondary hypertension
• Volume overload
![Page 58: Evaluation and management of hypertension](https://reader033.fdocuments.us/reader033/viewer/2022051314/559714331a28ab47108b47cb/html5/thumbnails/58.jpg)
How to improve maintenance of therapy ?
• Be aware of the problems leading to non-
compliance
• Articulate the goal of therapy - near-
normotension with few or no side effects.
• Educate the patient about the disease and its
treatment
![Page 59: Evaluation and management of hypertension](https://reader033.fdocuments.us/reader033/viewer/2022051314/559714331a28ab47108b47cb/html5/thumbnails/59.jpg)
• Maintain contact with patient
• Keep therapy inexpensive and simple
• Prescribe according to pharmacologic
principles
• Stop unsuccessful therapy and try different
drugs
![Page 60: Evaluation and management of hypertension](https://reader033.fdocuments.us/reader033/viewer/2022051314/559714331a28ab47108b47cb/html5/thumbnails/60.jpg)
• Anticipate and address side-effects
• Add effective and tolerated drugs stepwise
• Provide feedback and validation of success.
![Page 61: Evaluation and management of hypertension](https://reader033.fdocuments.us/reader033/viewer/2022051314/559714331a28ab47108b47cb/html5/thumbnails/61.jpg)
Recent advances
• Self – Management Support
• Renal sympathetic dennervation
• Baroreceptor stimulation
![Page 62: Evaluation and management of hypertension](https://reader033.fdocuments.us/reader033/viewer/2022051314/559714331a28ab47108b47cb/html5/thumbnails/62.jpg)
Thank you !